

Precision Biosciences Inc. (DTIL)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001357874

Precision Biosciences Inc.		
DTIL; healthcare		
Grade	E	A B C D E weakest fifth of 371 graded peers percentile 92.2; sampling error 2.5 points; lower is stronger
Rank	342 of 371	
Profitability	E	percentile 93.2
Solvency	C	percentile 44.8
Growth and financing	D	percentile 69.3
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025	
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$120M to \$591M assets total assets \$154.4M	
Standard universe	inside revenue above \$1M and assets above \$10M	
Warnings	dilution; fortress balance sheet	
Inputs computable	7 of 14	
Graded from	filings received through Mar 12, 2026 211 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026	
Last close	\$6.43 2026-10-08; market equity \$177.5M	
Price used in grade	None	

E, the bear
weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it

Nov Jan Mar May Jul Sep

\$5 \$6.43

Rescans on file: C/D from Apr 21, 2023, C from Mar 21, 2024, E from Apr 21,

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 93.2						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		13.8%	(6.6%)	93.2	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 44.8						
Twelve-month failure probability		0.19%	0.07%	68.0	248	2026-06-30
Altman Z double-prime		(7.20)	(0.31)	56.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Current ratio		13.32x	2.96x	9.5	839	2025-12-31
Growth and financing, sleeve percentile 69.3						
Revenue growth, three-year compound		10.9%	10.0%	47.3	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(13.4%)	2.1%	73.7	704	2025-12-31
Net share issuance, one year		135.9%	2.5%	86.7	634	2026-03-05


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 135.9%
Fortress balance sheet	cash minus debt is 167,353,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
337	Q32 Bio Inc. (QTTB)	90.8	E	
338	Editas Medicine, Inc. (EDIT)	91.1	E	fortress
339	Dyadic International Inc. (DYAI)	91.4	E	balance sheet short runway,
340	Century Therapeutics, Inc. (IPSC)	91.6	E	distress dilution,
341	Beyond Air, Inc. (XAIR)	91.9	E	fortress balance sheet dilution, short
342	Precision Biosciences Inc. (DTIL) <	92.2	E	runway, distress dilution,
343	Elutia Inc. (ELUT)	92.4	E	fortress balance sheet short runway,
344	Airsculpt Technologies, Inc. (AIRS)	92.7	E	fortress balance sheet late filer
345	Sutro Biopharma, Inc. (STRO)	93.0	E	dilution, short runway, distress,
346	China Pharma Holdings, Inc. (CPHI)	93.2	E	fortress balance sheet dilution, late
347	Fortress Biotech, Inc. (FBIO)	93.6	E	filer fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	38.4%	8.0%	70
Distance from 52-week high	(30.7%)	(31.4%)	51
EBIT to enterprise value	(45.9%)	(1.5%)	15
Free cash flow yield	(37.1%)	(1.0%)	16
Book value to price	0.26	0.28	47
Sales to price	0.19	0.31	38
Composite equity issuance, five years	267.6%	20.3%	94
Relative strength against the sector, log excess return	0.11	(0.14)	70

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	

Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$86.1M
Operating cash flow, four quarters	-\$51.9M
Months of runway	19.9
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$1.8M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$45.7M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$65.8M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
3	assets	us-gaap:Assets	\$154.4M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
4	assets	us-gaap:Assets	\$136.4M	2024-12-31	2026-03-12	10-K	0001628280-26-017019
5	current assets	us-gaap:AssetsCurrent	\$118.7M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
6	current liabilities	us-gaap:LiabilitiesCurrent	\$8.9M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$528.2M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
8	operating income	us-gaap:OperatingIncomeLoss	-\$52.1M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
9	book equity	us-gaap:StockholdersEquity	\$92.2M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
10	liabilities	us-gaap:Liabilities	\$62.2M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
11	operating income	us-gaap:OperatingIncomeLoss	-\$26.2M	2024-12-31	2026-03-12	10-K	0001628280-26-017019
12	interest expense	us-gaap:InterestExpense	\$1.8M	2024-12-31	2025-03-26	10-K	0000950170-25-044775
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$34.3M	2025-12-31	2026-03-12	10-K	0001628280-26-017019
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$68.7M	2024-12-31	2026-03-12	10-K	0001628280-26-017019
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$48.7M	2023-12-31	2025-03-26	10-K	0000950170-25-044775
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$25.1M	2022-12-31	2024-03-27	10-K	0000950170-24-036817
17	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$85,000	2025-12-31	2026-03-12	10-K	0001628280-26-017019
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$58.4M	2024-12-31	2026-03-12	10-K	0001628280-26-017019
19	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$250,000	2024-12-31	2026-03-12	10-K	0001628280-26-017019
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$84.1M	2023-12-31	2025-03-26	10-K	0000950170-25-044775
21	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$2.0M	2023-12-31	2025-03-26	10-K	0000950170-25-044775
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$45.8M	2022-12-31	2024-03-27	10-K	0000950170-24-036817
23	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$3.3M	2022-12-31	2024-03-27	10-K	0000950170-24-036817
24	assets	us-gaap:Assets	\$159.8M	2023-12-31	2025-03-26	10-K	0000950170-25-044775
25	assets	us-gaap:Assets	\$238.2M	2022-12-31	2024-03-27	10-K	0000950170-24-036817
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	24,726,695	2026-03-05	2026-03-12	10-K	0001628280-26-017019
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,481,931	2025-03-20	2025-03-26	10-K	0000950170-25-044775